Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Nephronectin (NPNT), also known as POEM (preosteoblast epidermal growth factor-like repeat protein with meprin) or EGFL6L, is a new type of extracellular matrix found in mouse embryo kidneys, with a molecular weight of 70 ~ 90 kDa. It is a new ligand for integrin α8β1. The NPNT gene is located on chromosome 4q24 and contains 13 exons. Its transcriptional expression is of great significance in physiological functions such as cell proliferation, differentiation, adhesion, apoptosis, and metabolism and in the pathological processes of various tissues or organ diseases.
NPNT is involved in human development and is expressed in multiple organs and tissues of embryos, newborns, and adults, such as embryonic urogenital spinal ureteral epithelial cells. NPNT mRNA was age-related. On day 13.5 of embryonic development (E13.5), NPNT was expressed in choroid plexus, jaw, ectoderm, developing teeth, lung basal layer, stomach, esophagus, ear and other tissues and organs. In newborns, NPNT is also expressed in the lens and taste buds; in adults, NPNT is expressed in the kidney, lung, brain, blood vessels, and thyroid.
Figure 1. Regulation of nephronectin gene expression by TGF-β, TNF-a and OSM. (Yamada A, et al. 2016)
NPNT and Tumor
Studies have shown that NPNT expression is reduced in mouse metastatic breast cancer models and is associated with organ metastasis. NPNT was expressed in the lung and liver tissues of the control animals, but the NPNT expression was lost in the metastatic tumors on the 25th day, suggesting that the NPNT deletion may help to form a metastatic environment for cancer cells. However, other researchers have established a spontaneous bone metastasis model of breast cancer and analyzed the role of extracellular matrix NPNT through genomic analysis, and found that it is specifically expressed in highly metastatic tumor epithelial cells. Inhibition of NPNT expression can significantly reduce the spontaneous metastasis of tumor cells in the lung, bone, and kidney.
Steigedal et al. comprehensively analyzed the expression pattern and distribution of NPNT in tissue microarrays of 842 breast cancer patients, and found that there was a correlation between cytoplasmic particle staining (<10% of tumor cells) and poor prognosis. NPNT promotes adhesion and anchoring independent growth through its integrin binding and enhancer motifs, and promotes the colonization of breast tumor cells in the lung, suggesting that NPNT may be a new type of prognostic indicator for breast cancer patients. Studies have shown that NPNT is reduced or absent in most melanoma cell lines and malignant melanoma tissues. NPNT increases cell adhesion and reduces cell migration and invasion, while NPNT deletion promotes tumor progression.
NPNT and Kidney Disease
Studies have shown that NPNT continues to be highly expressed during kidney development, while NPNT or integrin α8β1 knockout mice often show renal dysgenesis or organ defects, suggesting that NPNT may participate in kidney development by binding integrin α8β1. The expression of glial cell line-derived neurotrophic factor (Gdnf) in NPNT gene knockout mice decreased significantly, suggesting that NPNT gene can activate Gdnf.
The researchers studied 190 biopsy specimens of different types of kidney disease and found that NPNT was highly expressed in the dilated mesangial matrix of 18 patients with diabetic nephropathy. In addition, it is negatively expressed in other kidney diseases (eg, IgA glomerulonephritis, membranoproliferative glomerulonephritis, lupus nephritis, and membranous glomerulonephritis). This result suggests that NPNT can assist the diagnosis of diabetic nephropathy. Studies have shown that NPNT may participate in the pathophysiology of acute tubular necrosis cell regeneration and repair, and promote renal tubular epithelial cell proliferation. The increased expression of NPNT in acute tubular necrosis and regenerating renal tubular epithelial cells during the recovery period suggests that NPNT may be a potential biomarker.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.